Point72 Asia (Singapore) Pte. Ltd. Supernus Pharmaceuticals, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $381 Billion
- Q1 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 2,587 shares of SUPN stock, worth $83,172. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,587
Previous 209
1137.8%
Holding current value
$83,172
Previous $7.55 Million
1021.73%
% of portfolio
0.02%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SUPN
# of Institutions
305Shares Held
60.8MCall Options Held
8.8KPut Options Held
6.3K-
Black Rock Inc. New York, NY10.4MShares$334 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.16MShares$198 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$167 Million2.59% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$93.4 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.7MShares$86.8 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.72B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...